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           Melanoma is the most aggressive form of skin 
cancer. Invasion of melanoma cells into the dermis 
and subsequent metastatic dissemination are hall-
marks of melanoma progression (  1  ). One of the 
earliest steps in melanoma development includes 
disruption of E-cadherin  –  mediated adhesive in-
teractions between melanocytes and keratino-
cytes (  2  ). This disruption is accompanied by 
increased expression of N-cadherin, which facili-
tates cluster formation and invasion of melanoma 
into the dermis (  3  –  5  ). 
  The Snail1 transcription factors trigger epithe-
lial-mesenchymal transition (EMT) and have been 
shown to be important markers for tumor pro-
gression and invasion (  6  –  8  ). Although EMT was 
originally defi  ned as the formation of mesenchy-
mal cells with migratory and invasive properties 
from epithelia during development, there is also 
evidence that EMT plays a crucial role in tumor 
progression and metastasis (  9  ). Snail1-induced 
EMT has been mainly attributed to the direct re-
pression of E-cadherin transcription (for review 
see references [  10, 11  ]). We have previously 
shown that Snail1 is highly up-regulated in mela-
noma cells (  12  ). The signals responsible for Snail1 
up-regulation in melanoma are unclear, although 
several mechanisms for the regulation of Snail1 
expression in other cell types have been put for-
ward. For example, in epithelial cells, Snail1 ex-
pression can be induced by TGF-    , oncogenic 
Ras, or integrin-linked kinase (  13  –  15  ). 
  CYLD was originally identifi  ed as a tumor 
suppressor that is mutated in familial cylindroma-
tosis (Brooke-Spiegler syndrome), an autosomal-
dominant predisposition to multiple tumors of 
skin appendages (  16  ). CYLD contains a C-ter-
minal ubiquitin C-terminal hydrolase domain, 
which enables it to act as a deubiquitination en-
zyme (  17  –  19  ). CYLD was shown to remove 
ubiquitin chains from target proteins such as 
BCL-3, resulting in inhibition of nuclear translo-
cation of BCL-3, association with NF-    B p50 
and p52, and cell proliferation (  20  ). 
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  High malignancy and early metastasis are hallmarks of melanoma. Here, we report that the 
transcription factor Snail1 inhibits expression of the tumor suppressor CYLD in melanoma. 
As a direct consequence of CYLD repression, the protooncogene BCL-3 translocates into the 
nucleus and activates   Cyclin D1   and   N-cadherin   promoters, resulting in proliferation and 
invasion of melanoma cells. Rescue of CYLD expression in melanoma cells reduced prolif-
eration and invasion in vitro and tumor growth and metastasis in vivo. Analysis of a tissue 
microarray with primary melanomas from patients revealed an inverse correlation of Snail1 
induction and loss of CYLD expression. Importantly, tumor thickness and progression-free 
and overall survival inversely correlated with CYLD expression. Our data suggest that 
Snail1-mediated suppression of CYLD plays a key role in melanoma malignancy. 
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correlated with progression-free and overall survival of pa-
tients. Together, these data suggest that Snail1-mediated sup-
pression of CYLD plays a key role in melanoma malignancy 
and that CLYD represents a prognostic marker and potential 
therapeutic target of this highly aggressive tumor. 
    RESULTS   
  CYLD expression is down-regulated in melanoma 
  To get a fi  rst insight into the role of CYLD in malignant 
melanoma, we evaluated-CYLD expression in six diff  erent 
human melanoma cell lines, as well as in freshly isolated hu-
man melanoma cells. We found strong reduction of CYLD 
mRNA (  Fig. 1 A  ) and protein (  Fig. 1 B  ) levels when compared 
  In this study, we identifi  ed a signaling pathway that pro-
motes mitogenic and metastatic properties of melanoma by 
down-regulation of CYLD through the action of Snail1, 
whose expression is induced by BRAF-mediated activation of 
extracellular signal  –  regulated kinase (ERK). Snail1-dependent 
inhibition of CYLD transcription results in stimulation of Cy-
clin D1 and N-cadherin expression in melanoma cells, leading 
to enhanced proliferation, migration, and invasiveness of mela-
noma cells in vitro, as well as tumor growth and metastasis in 
vivo. Importantly, in melanoma tissue, Snail1 induction corre-
lated with the loss of CYLD expression, and both were linked 
to Clark level (tumor invasiveness) and tumor thickness. In-
creased Snail1 expression and reduced CLYD levels inversely 
    Figure 1.         Reduced CYLD expression in malignant melanoma.   Quantitative RT-PCR (A) and immunoblot analysis (B) showing CYLD expression in 
six human melanoma cell lines (Mel Im, Mel Juso, Mel Ei, Mel Ju, Mel Ho, and Mel Wei) and freshly isolated primary melanoma cells from two donors 
(MM1 and MM2) compared with NHEMs. (C) CYLD mRNA expression in NHEMs, primary melanomas (PT), and metastases of lymph nodes (LN), sentinel lymph 
nodes (SLN), and two distant metastases of malignant melanomas (M). Experiments in A  –  C were repeated at least three times. Data are the mean   ±   SEM. 
(D) Immunohistochemistry showing strong down-regulation or loss of CYLD (red staining) in primary malignant melanoma (indicated by arrows; I) and in 
melanoma metastasis (II). In III, CYLD staining in normal skin is presented. Strong CYLD staining is shown in keratinocytes in normal epidermis (I, III), 
which is indicated by *. For counterstaining, hematoxylin was used. Experiments were performed four times independently. (E) CYLD immunoreactivity of 
normal skin showing CYLD staining (green) and tyrosinase-marked melanocytes (red; Ia and Ib). Higher magnifi  cation images (II) indicate a melanocyte 
displaying expression of both proteins. Experiments were performed three times independently. (F) Quantifi  cation of CYLD and tyrosinase costaining in 
epidermal melanocytes. Fraction of tyrosinase-expressing cells (melanocytes) that are expressing CYLD at low, moderate, or high levels (Tyrosinase/CYLD). 
Bars: (D) 100   μ  m; (E, Ia and Ib) 100   μ  m; (E, II) 5   μ  m.     JEM VOL. 206, January 19, 2009 
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with normal human epidermal melanocytes (NHEMs).   Also, 
in situ, primary melanomas and melanoma metastases dis-
played strongly down-regulated or absent CYLD mRNA 
(  Fig. 1 C  ) and protein (  Fig. 1 D  ). In contrast, melanocytes in 
normal epidermis displayed high CYLD expression, as con-
fi  rmed by costaining for tyrosinase and CYLD and quantifi  -
cation of costaining (  Fig. 1, E and F  ). Because mutations and 
promoter methylation of the   CYLD   gene could be excluded 
(unpublished data), we concluded that down-regulation of 
CYLD likely occurs at the transcriptional level. 
  Snail1 affects transcriptional expression of CYLD 
in melanoma cells 
  Analysis of the   CYLD   promoter revealed three potential bind-
ing sites for the transcriptional repressor Snail1 (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20082044/DC1). 
We found that Snail1 messenger RNA (mRNA) was highly 
increased in melanoma cell lines compared with NHEM, 
an expression pattern that correlated inversely with CYLD 
(Fig. S2 A vs.   Fig. 1 A  ). In contrast, expression of Snail2 
(Snai2), a Snail1 homologue that has been shown to aff  ect 
expression of several genes important for melanoma progres-
sion (  21  ), in melanoma was similar or lower than in NHEM 
(Fig. S2 A). 
  Chromatin immunoprecipitation (ChIP) assays demon-
strated Snail1 binding to the   CYLD   promoter in primary 
melanoma cells and the melanoma cell lines Mel Im and Mel 
Juso, but not in NHEM (  Fig. 2 A  ).   Furthermore, neither 
Snail2 nor Twist (another E-box binding factor associated 
with poor prognosis in melanoma [  22  ]) bound to the CYLD 
promoter in ChIP assays (  Fig. 2 A  ). Snail1 recruitment to the 
  CYLD   promoter was observed to the fi  rst E-box at position 
    19 to     14, which resembles the consensus Snail1 binding 
    Figure 2.         Snail1 inhibits transcriptional expression of CYLD in mela-
nocytic cells.   (A) Lysates from NHEMs, primary melanoma cells (MM1 and 
MM2), and melanoma cell lines (Mel Im, Mel Juso) were examined by ChIP 
assay using an anti-Snail1, anti-Twist, and anti-Snail2  –  specifi  c antibody, 
respectively, as well as a PCR primer pair corresponding to the promoter of 
the   CYLD   gene. Recruitment to the   CYLD   promoter was only shown for 
Snail1. Snail1, Twist, Snail2, immunoprecipitation (IP) using specifi  c anti-
bodies; IgG, IP using negative control rabbit immunoglobulin; Input, 10% of 
the cell lysate used for the IP is shown. (B) Reporter assays revealing induc-
ible   CYLD   promoter (    550 to     1 bp) activity in Mel Im cells after transient 
transfection with asSnail (asSnail), whereas transfection with Snail1 expres-
sion plasmid (Snail1) completely abrogated   CYLD   promoter activity com-
pared with the control (pGL3). Mutation of the consensus Snail1 binding 
site (CYLD mut-19) led to strong promoter activity that was not affected by 
transfection with asSnail or Snail1. Data are given as mean   ±   SEM. *, P   <   
0.05 compared with CYLD control. (C) Immunoblot analysis showing that 
CYLD protein is up-regulated in Mel Im cells after stable transfection with 
asSnail expression plasmids (clone 1 and clone 2; top) and after transient 
transduction with Snail1 siRNA nucleotides (siRNA Snail1) or scrambled 
siRNA control (siRNA control; bottom). Nontransduced Mel Im cells were 
used as control. (D) Quantitative RT-PCR analysis showing increased CYLD 
mRNA expression in three different melanoma cell lines (Mel Im, Mel Ei, and 
Mel Juso) and melanoma cells (MM1 and MM2) transiently transfected with 
asSnail expression plasmids compared with mock-transfected (pcDNA3) 
cells. Data are given as mean   ±   SEM. *, P   <   0.05. (E) Western blot analysis 
showing decreased CYLD protein expression in NHEM cells transiently 
transfected with Snail1 expression plasmids compared with mock-trans-
fected (pcDNA3) or nontransfected (NHEM) cells. (F) ERK inhibition by treat-
ment with MEK inhibitors PD98059 and UO126 signifi  cantly affects Snail1 
and CYLD mRNA expression in Mel Im cells. JNK inhibition (SP600125) 
exhibits no effect compared with vehicle (DMSO) control. Data are given as 
mean   ±   SEM. *, P   <   0.05. ns, not signifi  cant, both compared with Control. 
(G) Quantitative RT-PCR revealing that inhibition of ERK by PD98059 or 
UO126 further induced CYLD expression in melanocytes. JNK inhibition 
(SP600125) exhibits no effect compared with vehicle (DMSO) control. Data 
are given as mean   ±   SEM. *, P   <   0.05. Experiments in A  –  G were repeated at 
least three times. (H) Detection of CYLD expression by Western blot analysis. 
Transfection of NHEMs with mutated BRAF (V600E) induced Snail1 protein 
expression and, consequently, CYLD protein suppression, whereas no 
changes were found after transfection of wild-type BRAF (wtBRAF). Experi-
ments were repeated three times with cells from two different donors.    
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morigenicity of melanoma cells via repression of CYLD, the 
two melanoma asSnail clones (  Fig. 2 D  ) were stably trans-
duced with viral vectors encoding siRNA against CYLD, re-
sulting in complete suppression of CYLD (  Fig. 3 A  ).   
sequence (CAGGTG; Fig. S1), but not to E-box II (-382 to 
-377) or III (    429 to     424; unpublished data). 
  Reporter gene assays using the CYLD promoter (    550 
to     1) revealed inducible activity in melanoma cells after 
transient transfection with an antisense Snail1 construct (as-
Snail). Conversely, transient transfection of a Snail1 expres-
sion construct completely repressed CYLD promoter activity 
(  Fig. 2 B  ). Mutation of the fi  rst E-box of the CYLD pro-
moter at position     19 resulted in strong promoter activity in 
Mel Im cells, which was not aff  ected by transient transfection 
with asSnail or Snail1 (  Fig. 2 B  ). In contrast, mutations in 
E-box II or III of the CYLD promoter did not change the re-
porter activity (unpublished data). 
  These data indicate that recruitment of Snail1 to the fi  rst 
E-box binding site located in the CYLD promoter suppresses 
CYLD promoter activity in malignant melanoma. 
  To further assess the eff  ect of Snail1 on CYLD expression 
in melanoma cells, we either stably transfected Mel Im cells 
with asSnail expression plasmids or depleted Snail1 with spe-
cifi  c siRNAs, and found a strong up-regulation of CYLD 
protein (  Fig. 2 C  ). Furthermore, transient expression of as-
Snail expression plasmids was suffi   cient to induce CYLD ex-
pression in melanoma cell lines and primary human melanoma 
cells (  Fig. 2 D   and Fig. S2 B). Accordingly, transient transfec-
tion of NHEM with a Snail1 expression plasmid strongly in-
hibited CYLD expression (  Fig. 2 E  ). 
  BRAF-mediated ERK activation induced Snail1 and down-
regulated CYLD in melanoma cells 
  Snail1 transcription depends on ERK signaling in squamous 
cell carcinoma and epithelial cells (  15, 23  ), and melanoma 
cells exhibit high ERK activity compared with NHEMs (  24  ). 
Interestingly, we found that pharmacological inhibition of 
the ERK/mitogen-activated protein kinase (MAPK) cascade 
induced an almost complete loss of Snail1 mRNA expression 
and signifi  cantly increased CYLD mRNA levels in melanoma 
cells (  Fig. 2 F  ). In accordance, treatment of NHEM with 
ERK inhibitors to further reduce basal levels of ERK activity 
also increased expression of CYLD (  Fig. 2 G  ). 
  As BRAF activity acts upstream of ERK, and V600E mu-
tations of BRAF are common in melanoma development (in 
accordance to our fi  nding that BRAF mutations are present 
in all melanoma cell lines used in this study [unpublished 
data]), we tested whether mutated BRAF can modulate 
CYLD regulation in NHEM. Transfection of NHEM with 
V600E BRAF resulted in up-regulation of Snail1 and down-
regulation of CYLD expression levels (  Fig. 2 H  ). 
  Collectively, these data indicate that high Snail1 ex-
pression modulated by BRAF-mediated ERK activity is 
involved in the transcriptional down-regulation of CYLD 
in melanoma. 
  Snail1 regulates tumorigenicity in melanoma 
via CYLD repression 
  Snail1 has been shown to play an important role in progres-
sion of melanoma. To study whether Snail1 facilitates tu-
    Figure 3.         Snail1 regulates tumorigenicity via CYLD repression.  
(A) Western blot analysis of two Mel Im asSnail clones (clone 1 and clone 
2) applying CYLD, Cyclin D1, and N-cadherin antibodies. Stable transduc-
tion with viral vectors encoding siRNA against CYLD (siRNA CYLD) results 
in the complete depletion of CYLD, but induction of Cyclin D1 and N-
cadherin in both clones. Transduction with control siRNA (siRNA control) 
exhibits no effect. Proliferation (B) and migration (C; in monolayer scratch 
assays) of Mel Im control cells (Control) and Mel Im asSnail clone 1 either 
stably transduced with viral vectors encoding siRNA against CYLD (siRNA 
CYLD), control siRNA (siRNA control), or without transduction (asSnail). 
Data represent proliferation after 72 h, and areas between scratch fronts 
(after 2 d in monolayer scratch assays) and are given as mean   ±   SEM. *, 
P   <   0.05. Experiments in A  –  C were repeated at least three times. (D) Growth 
of Mel Im asSnail clone 1 (asSnail) transduced with siRNA against CYLD 
(siRNA CYLD) or control siRNA (siRNA control) and Mel Im control cells 
(Control) after s.c. implantation into nude mice (10  6   cells/mouse).  Bars 
represent mean tumor size (  ±   SEM) 3 wk after implantation. *, P   <   0.05. 
(E) Histological analysis of the growths of Mel Im asSnail clone 1 without 
transduction (I) or stably transduced with siRNA against CYLD (II) 3 wk 
after s.c. implantation into nude mice. Pictures are representative and 
arrows indicate diffuse infi  ltration in II, whereas nodular growth (*) ap-
pears in I. Bar, 200   μ  m. Experiments and analysis in D and E, respectively, 
have been performed with 10 mice/group.     JEM VOL. 206, January 19, 2009 
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  Suppression of Snail1 in Mel Im cells resulted in signifi  -
cantly impaired proliferation (  Fig. 3 B  , clone 1; Fig. S3 A, 
clone 2, available at http://www.jem.org/cgi/content/full/
jem.20082044/DC1) and migration rates (  Fig. 3 C  , clone 1; 
Fig. S3 B, clone 2) compared with control cells. siRNA-me-
diated depletion of CYLD almost completely rescued the 
proliferative and migratory potential of Snail1-depleted mel-
anoma cells (  Fig. 3, B and C,   and Fig. S3, A and B). 
  To assess the relevance of Snail1-mediated tumor pro-
gression in vivo, we used a xenograft tumor model. Mel Im 
asSnail clones formed signifi  cantly smaller tumors than Mel 
Im control cells when injected subcutaneously into nude 
mice. In contrast, CYLD siRNA reconstituted the dimin-
ished growth of Mel Im antisense Snail1 clones (  Fig. 3 D  ). 
Histological analysis of tumors formed by Mel Im asSnail 
clones in nude mice revealed nodular growth (  Fig. 3, E, I  ). In 
contrast, Mel Im asSnail clones transduced with siRNA 
against CYLD showed more diff  use infi  ltration of the sur-
rounding tissue (  Fig. 3, E, II  ). 
  These fi  ndings indicate that CYLD plays an important 
role in Snail1-mediated progression of melanoma. 
  CYLD regulates N-cadherin and Cyclin D1 expression 
via BCL-3 in melanoma 
  We have shown in a previous study that BCL-3 associates 
with the NF-    B p50 or p52 subunits to enhance cell prolif-
eration by activating the   Cyclin D1   promoter in mouse kera-
tinocytes (  17  ). CYLD prevents nuclear accumulation of 
BCL-3 and hence reduces Cyclin D1 expression and prolif-
eration of keratinocytes. 
  Next, we examined whether a similar mechanism oper-
ates in human melanoma cells. In contrast to NHEM, BCL-3 
was primarily found in the nucleus of the melanoma cell lines 
(Fig. S4 A, available at http://www.jem.org/cgi/content/
full/jem.20082044/DC1). Transduction with lentiviral vec-
tors expressing CYLD prevented nuclear translocation of 
BCL-3 (Figs. S4, B and C), whereas a catalytically inactive 
mutant of CYLD (CYLD C/S) still binding to BCL-3 was 
unable to prevent nuclear translocation (Fig. S4, C and D). 
  To analyze whether CYLD is also regulating Cyclin D1 
expression in melanoma cell lines, Mel Im and Mel Juso cells 
were transduced with viral vectors carrying CYLD. Clones 
expressing CYLD at similar levels as NHEMs were used as 
demonstrated by Western blot analysis (  Fig. 4 A  ).   In agree-
ment with the mechanism in keratinocytes (  17  ), CYLD 
markedly reduced expression of Cyclin D1 (  Fig. 4 B  ),   cyclin 
D1   promoter activity (  Fig. 4 C  ), and BCL-3 recruitment 
    Figure 4.         CYLD regulates N-cadherin and Cyclin D1 expression via 
BCL-3 in melanoma.   (A) Western blot analysis revealing CYLD expression 
in NHEMs and Mel Im and Mel Juso cells stably transduced with CYLD, but 
not in melanoma cells stably transduced with GFP. Actin labeling is used as 
loading control. (B) Western blot detecting Cyclin D1 expression in Mel Im 
cells stably transduced with CYLD, but not in nontransduced control cells or 
cells stably transduced with GFP. Tubulin labeling is used as loading control. 
(C) Effect of transfection of a CYLD expression vector carrying wild-type 
(CYLD) or mutated CYLD (CYLD C/S) on   Cyclin D1   promoter activity in Mel 
Im cells. Data are given as mean   ±   SEM. *, P   <   0.05 versus pcDNA3 empty 
vector used as control. (D) Lysates from Mel Im cells (Control) and CYLD, 
mutant CYLD (CYLD C/S), or GFP stably expressing Mel Im cells were exam-
ined by ChIP assay using specifi  c polyclonal antibodies against BCL-3, p50, 
or p52, and PCR primer pairs corresponding to the promoter of the   Cy-
clinD1   or   N-cadherin   gene to analyze recruitment of BCL-3 to the   Cyclin D1  
and   N-cadherin   promoter. BCL-3, p50, and p52 immunoprecipitation (IP) 
using polyclonal antibodies as indicated. IgG, negative control rabbit IgG 
(DAKO); Input, 10% of the cell lysate used for the IP is shown. (E) Effect of 
transduction of a CYLD expression vector carrying wild-type (CYLD) or a 
catalytic inactive mutant of CYLD (CYLD C/S) on   N-cadherin   promoter  activ-
ity in Mel Im cells. Data are given as mean   ±   SEM. *, P   <   0.05 versus 
pcDNA3 empty vector used as control. (F) Western blot analysis of CYLD, 
Snail1, Snail2, Twist, E-cadherin, N-cadherin, and Actin expression in non-
transduced Mel Im cells (Control) or Mel Im cells transduced with GFP or 
CYLD. (G) Western blot analysis of BCL-3, Cyclin D1, N-cadherin, Snail1, and 
Actin expression in nontransduced Mel Im and Mel Juso cells (Control), cells 
transduced with the BCL-3 siRNA nucleotides (siRNA BCL-3), or scrambled 
siRNA control (siRNA control). (H) Western blot analysis of Snail1, CYLD, 
(nuclear) BCL-3, and Actin expression in nontransduced Mel Im cells (Con-
trol), and cells transduced with Snail1 siRNA nucleotides (siRNA Snail1) or 
scrambled siRNA control (siRNA control). Experiments in A  –  H were repeated 
at least three times.    
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vectors carrying a catalytically inactive mutant of CYLD (C/
S-CYLD), a GFP expression cassette or noninfected cells. 
  Because melanoma cells with BRAF V600E mutation 
exhibit an increased production of the immunosuppressive 
IL-10 (  25  ), and the production of IL-10 is reduced in BCL-
3  –  null cells (  26  ), we further analyzed BCL-3 binding to the 
IL-10 promoter. CYLD, but not C/S-CYLD, abrogated 
BCL-3 binding of IL-10 promoter, confi  rming the important 
role of CYLD in the regulation of BCL-3 (Fig. S4 E). 
  In addition to uncontrolled proliferation, malignant mela-
noma is characterized by early invasiveness and metastasis. One 
of the hallmarks of the increased migratory and invasive poten-
tial of malignant melanoma cells is the expression of N-cadherin 
(  2  –  4  ). Interestingly, the   N-cadherin   gene contains NF-    B bind-
ing sites in its promoter region (  27  ). ChIP analysis revealed 
DNA-bound BCL-3 in a complex with p50 or p52 in control 
cells, and CYLD C/S –   or GFP-expressing cells, whereas CYLD-
expressing cells showed no BCL-3 recruitment to the NF-    B 
binding sites of the   N-cadherin   promoter (  Fig. 4 D  , right). 
  In line with these fi  ndings, expression of CYLD in mela-
noma cells strongly reduced   N-cadherin   promoter activity (  Fig. 
4 E  ) and protein levels (  Fig. 4 F  ), whereas no eff  ects on Snail1, 
Snail2, Twist, or E-cadherin expression (  Fig. 4 F  ) were found 
compared with GFP- or CYLD C/S  –  transduced controls, 
respectively. In agreement, down-regulation of CYLD in as-
Snail clones 1 and 2 resulted in up-regulation of Cyclin D1 
and N-cadherin (  Fig. 3 A  ). 
  Depletion of BCL-3 expression in melanoma cells using 
siRNA resulted in reduced expression of both N-cadherin 
and Cyclin D1 without changes in Snail1 expression levels 
(  Fig. 4 G  ). Furthermore, siRNA against Snail1, which up-
regulated CYLD expression (  Fig. 4 H  ), reduced nuclear 
BCL-3 levels, confi  rming that reexpression of CYLD blocks 
nuclear translocation of BCL-3 in melanoma (  Fig. 4 H  ). 
  These results suggest that BCL-3  –  induced cyclin D1 and 
N-cadherin expression is blocked by the expression of CYLD. 
  CYLD regulates proliferation and N-cadherin  –  mediated 
migration and invasion in melanoma 
  To investigate the functional role of the suppressive eff  ect of 
CYLD on Cyclin D1 and N-cadherin, we used the two diff  er-
ent melanoma cell lines (Mel Im and Mel Juso) stably express-
ing CYLD (  Fig. 4 A  ). CYLD expression caused diminished 
proliferation in Mel Im cells (  Fig. 5 A  ) and Mel Juso cells (Fig. 
S5 A, available at http://www.jem.org/cgi/content/full/jem
.20082044/DC1), as well as a decrease in colony growth in soft 
agar in both cell lines (  Fig. 5 B   and Fig. S5 B) compared with 
control, GFP, or CYLD C/S  –  infected cells.   
  Analysis of the motile and invasive phenotype of CYLD-
expressing melanoma cells revealed that CYLD expression 
resulted in diminished migration and invasion rates as assessed 
in time-lapse scratch assays (  Fig. 5 C   and Fig. S5 C), spheroid 
migration assays (  Fig. 5 D   and Fig. S5 D), and Boyden cham-
ber assays (  Fig. 5 E   and Fig. S5 E). 
  In contrast, forced expression of N-cadherin reversed 
the CYLD-mediated reduction in melanoma cell migration 
to the cyclin D1 promoter in a complex with p50 or p52 
(  Fig. 4 D  , left) as compared with cells transduced with viral 
    Figure 5.         CYLD regulates proliferation and N-cadherin  –  mediated 
migration and invasion.   (A) Proliferation of Mel Im cells expressing 
CYLD, CYLD C/S, or GFP versus the parental Mel Im cell line (Control) after 
72 h. Data are given as mean   ±   SEM. *, P   <   0.05. (B) Colony formation in 
soft agar 3 wk after plating 10  4   Mel Im cells expressing CYLD, CYLD C/S, or 
GFP versus the parental (Control) cell line. (C) Migration of melanoma 
cells in monolayer scratch assays. Mel Im cells transduced with lentiviral 
vectors carrying CYLD, CYLD C/S, or GFP and noninfected control cells 
(Control) were used. Representative pictures (at day 0  –  2) and calculation 
(mean   ±   SEM; *, P   <   0.05) of the areas between scratch fronts (after 2 d). 
(D) Migration of Mel Im cells (Control) compared with CYLD, CYLD C/S, or 
GFP stably transduced cells in spheroid migration assays. Data are given 
as mean   ±   SEM. *, P   <   0.05. (E) Invasion of Mel Im (Control) cells com-
pared with CYLD, CYLD C/S, or GFP stably transduced cells (after 24 h) in 
Boyden chamber assays. Data are given as mean   ±   SEM. *, P   <   0.05 com-
pared with Control and GFP. (F) Migration of melanoma cells in Boyden 
chamber assays. Comparison of Mel Im cells stably transduced with CYLD, 
CYLD C/S or GFP, and transiently cotransfected with an N-cadherin ex-
pression vector (+N-cadherin) or control vector (+pCMX). Data are given 
as mean   ±   SEM. *, P   <   0.05. (G) Migration of melanoma cells in monolayer 
scratch assays. Comparison of nontransduced Mel Im cells (Control), cells 
transfected with BCL-3 siRNA nucleotides (siRNA BCL-3), or scrambled 
siRNA control (siRNA Control). Data are given as mean   ±   SEM. *, P   <   0.05 
compared with Control or siRNA control. Experiments in A  –  G were re-
peated at least three times.     JEM VOL. 206, January 19, 2009 
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(  Fig. 5 F   and Fig. S5 F), and depletion of BCL-3 expression 
resulted in diminished migration rates (  Fig. 5 G   and Fig. S5 G). 
  These data indicate that CYLD regulates proliferation, as 
well as migration and invasion, of melanoma by controlling 
N-cadherin expression. 
    Figure 6.         CYLD inhibits proliferation and metastasis of melanoma 
cells in vivo  .     (A) Growth kinetic of tumors formed by Mel Im control cells 
(Control) or cells transduced with viral vectors carrying CYLD or GFP after 
subcutaneous implantation into nude mice (10  6   cells/mouse). Data repre-
sent mean tumor size (  ±   SEM) at different time points. *, P   <   0.05 versus 
both GFP and Control. (B) MIA serum levels in nude mice after i.v. injec-
tion of Mel Im control cells (Control) or cells transduced with viral vectors 
carrying CYLD or GFP (10  6   cells/mouse; 8  –  10 mice/group). Data represent 
mean MIA level (  ±   SEM) 4 wk after injection. (*, P   <   0.05 versus both GFP 
and Control). (C) Immunohistochemical MART1 staining of pulmonary 
tissue 4 wk after inoculation. Photomicrographs showing representative 
sections of the lung of mice receiving Mel Im cells transduced with CYLD 
or GFP. Bar, 200   μ  m. (D) Number of micrometastatic lesions per one rep-
resentative cross section of the lungs from each mouse. Data are given as 
mean   ±   SEM. *, P   <   0.05 compared with control and GFP. Experiments and 
analysis in A  –  D have been performed with 8  –  10 mice/group.     
    Figure 7.         CYLD expression in melanoma has prognostic implica-
tion.   Kaplan-Meier curves for overall survival (A) and progression-free 
survival (B) in melanoma patients with a positive immunosignal for CYLD 
(CYLD positive) or without detectable CYLD protein expression (CYLD neg-
ative). CYLD immunohistochemical staining of primary malignant mela-
noma tissue was performed using a tissue microarray consisting of 88 
cases. Investigation of CYLD protein expression was informative in all 
specimens. Kaplan-Meier curves for overall survival (C) and progression-
free survival (D) in melanoma patients with a positive immunosignal for 
Snail1 (Snail1 positive) or without detectable Snail1 protein expression 
(Snail1 negative). Snail1 immunohistochemical staining of primary malig-
nant melanoma tissue was performed using a tissue microarray consist-
ing of 88 cases. Immunohistochemical analysis of Snail1 was informative 
in 78 samples. (E) Examples of tissues with positive and negative CYLD 
and Snail1 staining, respectively. Bar, 100   μ  m. (F) Comparison of CYLD and 
Snail1 immunoreactivity. An inverse correlation of CYLD and Snail1 stain-
ing was observed.     
  CYLD inhibits proliferation and metastasis of melanoma 
cells in vivo 
  To test the eff  ect of CYLD on tumor growth in vivo, we 
used a murine xenograft model. Mel Im cells stably express-
ing CYLD were injected subcutaneously into nude mice, re-
vealing signifi  cantly impaired growth compared with cells 
stably expressing GFP or noninfected cells (  Fig. 6 A  ).   Similar 
results were obtained with Mel Juso cells (Fig. S6 A, available at 
http://www.jem.org/cgi/content/full/jem.20082044/DC1). 
14 d after injection, none of the mice from the CYLD group, 
but 6 out of 10 animals from the GFP and noninfected con-
trol groups, developed tumors. After 4 wk, 4 mice from the 228 SNAIL1 REGULATES CYLD IN MELANOMA   | Massoumi et al. 
siveness and tumor thickness     (  Table I  ).      Moreover, loss of 
CYLD expression inversely correlated with overall (  Fig. 7 A  ) 
and progression-free survival (  Fig. 7 B  ). In contrast, patients 
with primary tumors expressing CYLD developed no tracta-
ble metastasis in the time period analyzed. 
  Notably, and in accordance with the Snail1-CYLD con-
nection described here, expression of Snail1 was inversely 
correlated to CYLD expression in primary tumors (P   <   0.001; 
  Fig. 7, E and F  ). In compliance, Snail1 expression also corre-
lated with tumor thickness (  Table I  ) and overall (  Fig. 7 C  ) 
and progression-free survival (  Fig. 7 D  ). 
  These clinical fi  ndings support a link between the known 
tumor promoter Snail1 and its transcriptional target CYLD, 
indicating an important role for Snail1 to suppress CYLD 
during progression of melanoma and for CYLD to suppress 
melanoma cell proliferation and invasion. 
    DISCUSSION   
  The currently available adjuvant therapies for human mela-
noma have only limited eff  ects on overall survival and can 
have severe side eff  ects (for review see reference [  29  ]). This 
highlights the strong need for rational, mechanism-based 
therapies. One approach with great potential for achieving 
this goal is the identifi  cation and targeting of tumor-activated 
signaling cascades. 
  Our study uncovers a new key signaling pathway that is re-
sponsible for progression of malignant melanoma and is related 
to poor prognosis in melanoma patients. This novel molecular 
mechanism is based on the suppression of CYLD expression by 
the transcriptional regulator, Snail1, driving melanoma cells to 
an aggressive phenotype (depicted as a model in   Fig. 8  ).   
CYLD group also developed tumors; however, these tumors 
were signifi  cantly smaller (4.3   ±   2.8 vs. 28.6   ±   14.7 mm  3   
[GFP] and 28.5   ±   10.7 mm  3   [noninfected];   Fig. 6 A  ). 
  In addition, melanoma cells were injected i.v. into nude 
mice to assess in vivo metastasis. MIA serum levels are an es-
tablished marker to monitor melanoma metastasis (  28  ), and 
therefore, an ELISA selectively detecting human MIA was 
applied to monitor the serum content of MIA in this xeno-
graft model. 4 wk after injection, animals receiving CYLD-
expressing melanoma cells had signifi  cantly lower MIA serum 
levels (1.1   ±   0.4 ng/ml) than animals injected with GFP-
transduced (3.8   ±   0.8 ng/ml) or nontransduced (3.8   ±   1.6 
ng/ml) cells (  Fig. 6 B   and Fig. S6 B). 
  We performed immunohistochemical analysis sections 
using MART 1 and MIA, two tumor-associated antigens, to 
detect lung metastasis. Mice receiving Mel Im cells stably 
transduced with CYLD showed almost no MART 1 (  Fig. 6 C  ) 
or MIA (not depicted) staining compared with mice injected 
with control cells, indicating that they had signifi  cantly less 
metastatic deposits (  Fig. 6 D   and Fig. S6 C). 
  In summary, these data show that reduced CYLD expres-
sion induces tumorigenicity of melanoma, and that reexpres-
sion of CYLD reduces their tumor growth and metastasis 
in vivo. 
  Clinical relevance of Snail1-induced CYLD repression 
  To analyze the clinical relevance of reduced CYLD expres-
sion in melanoma, we performed immunohistochemical 
analysis of a tissue microarray consisting of 88 primary human 
melanomas (  Fig. 7 E  ) and found a signifi  cant correlation be-
tween loss of CYLD expression and Clark level/tumor inva-
  Table I.  CYLD and Snail1 immunoreactivity in relation to clinico-pathological characteristics 
CYLD IHC Snail1 IHC
Variable Categorization   n   analyz. neg. weak pos. 
  (score 1+)
strong pos. 
  (score 2+)
P    a     n   analyz. neg. pos. P    a   
Primary malignant melanomas    b   
Age at diagnosis   >  60 yr 48 25 16 7 0.647 43 16 26 1
  <  60 yr 40 23 14 3 36 13 23
Gender female 39 20 15 4 0.745 34 16 18 0.157
male 49 28 15 6 44 13 31
Clark level II-III 20 8 6 6   0.018 16 9 7 0.145
IV-V 67 39 24 4 61 20 41
Tumor thickness   <  1.75 mm 22 11 5 6   0.027 17 10 7   0.049 
  >  1.75 mm 66 37 25 4 61 19 42
Growth pattern NOS 11 5 4 2 0.854 8 3 5 0.505
SSM 38 20 12 6 36 14 22
ALM 6 5 1 0 5 0 5
NMM 30 16 12 2 27 11 16
LMM 3 2 1 0 2 1 1
CYLD and Snail1 immunohistochemical staining of primary malignant melanoma tissue was performed using a tissue microarray consisting of 88 cases. Investigation of CYLD 
protein expression was informative in all specimens, and immunohistochemical analysis of Snail1 was informative in 78 samples. NOS, not otherwise specifi  ed; SSM, 
superfi  cial spreading melanoma; ALM, acral lentiginous melanoma; NMM, nodular malignant melanoma; LMM, lentigo malignant melanoma.
  a  Fisher  ’  s exact test (two-sided). Signifi  cant data are shown is bold.
  b  Only initial and unifocal malignant melanomas were included.JEM VOL. 206, January 19, 2009 
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CYLD expression. Our fi  ndings indicate that after malignant 
transformation, constitutively high ERK activity and Snail1 
expression allow melanoma cells to permanently exploit tran-
scriptional repression of CYLD and activation of BCL-3 to 
acquire a more aggressive phenotype. 
  BRAF V600E mutation has been shown to induce NF-    B 
activity in human melanoma cell lines via regulation of     -Trcp 
expression (  32  ), and high NF-    B activity resulting in increased 
tumorigenesis has been reported in malignant melanoma 
(  32  –  34  ). Here, we provide a new mechanism for how muta-
tional activation of B-RAF contributes to both constitutive 
NF-    B and BCL-3 activity via repression of CYLD. 
  Loss of CYLD promoted BCL-3 recruitment to the   Cy-
clin D1   promoter. This mechanism plays an important role 
for the growth of melanoma cells because stable expression 
of CYLD in melanoma cells reduced tumor growth and me-
tastasis in vivo in a xenograft model. More importantly, 
we showed for the fi  rst time that BCL-3 is recruited to the 
  N-cadherin   promoter to activate transcription. Thereby, our study 
provides a novel paradigm of how CYLD aff  ects N-cadherin 
expression, which has been shown to correlate with tumor 
cell motility and invasiveness in several malignancies includ-
ing melanoma (  2, 12, 33  ). Re-expression of CYLD in mela-
noma cells with constitutively high Snail1 levels inhibited 
N-cadherin expression, leading to a reduced migratory and 
invasive potential in vitro and less pulmonary metastasis in 
a murine in vivo model. Conversely, depletion of CYLD in 
Snail1-defi  cient melanoma cells resulted in highly aggressive 
melanoma cells with strong proliferative and invasive po-
tential. In summary, these fi  ndings clearly demonstrate that 
suppression of CYLD is a central mechanism in how Snail1 
facilitates both growth and metastasis in malignant melanoma. 
Whether this mechanism operates in other types of cancer 
has to be tested. 
  Importantly, the clinical fi  ndings further support an im-
portant role of the Snail1 CYLD pathway in tumor progres-
sion and survival in melanoma patients. Snail1 expression 
shows signifi  cant correlation with loss of CYLD and signs of 
tumor progression like tumor thickness. Even more impor-
tant, both Snail1 and CYLD expression in primary tumors 
directly correlate with progression-free survival and overall 
survival of the patients. 
  Hence, elevated expression of Snail1 and reduced ex-
pression of CYLD in primary melanoma hint to a high 
metastatic potential in vivo. Although CYLD levels in pri-
mary tumor and melanoma might vary, our fi  ndings indi-
cate the intriguing possibility that analysis of CYLD and 
Snail1 protein expression in the primary tumor may be used 
as a predictive marker for survival of melanoma patients. 
Such prognostic risk assessment would have major clinical 
implications for the appropriate selection of treatment mo-
dalities and follow up protocols, or as stratifi  cation factor for 
adjuvant therapy. 
  Finally, our data also suggest a rationale for strategies to 
rescue CYLD expression in malignant melanoma as thera-
peutic approaches for this highly aggressive tumor. 
  Notably, our fi  ndings reveal a thus far unknown link be-
tween Snail1, which plays an important role in EMT and 
favors tumor progression (  9, 11  ), and CYLD. CYLD was 
originally identifi  ed as a tumor suppressor that is mutated in 
familial cylindromatosis (  16  ). In melanoma, we did not fi  nd 
mutations of the   CYLD   gene (unpublished data), but we 
identifi  ed direct recruitment of the transcriptional repressor 
Snail1 to the   CYLD   promoter as a molecular mechanism lead-
ing to strongly reduced or even absent CYLD expression in all 
melanoma tissues and cell lines tested. In accordance, mela-
noma cells in which Snail1 expression was abrogated showed 
a strong up-regulation of CYLD and reduced growth in vitro 
and in vivo. 
  Interestingly, we found that ERK activation is the major 
upstream signaling mechanism responsible for high constitu-
tive Snail1 expression in malignant melanoma cells, as well 
as for induced Snail1 expression in normal melanocytes. In 
melanoma cells, the Ras  –  Raf  –  MEK  –  ERK (MAPK) signaling 
pathway is constitutively active and exerts key functions in 
melanoma development and progression (  30  ). Activating 
mutations in BRAF or N-ras have been identifi  ed in most 
cutaneous melanomas (  31  ), corresponding to our fi  nding that 
BRAF mutations were present in all melanoma cell lines 
tested, but not in primary human melanocytes. 
  In contrast to melanoma cells, melanocytes express CYLD 
at a high level, exhibit low ERK activity, and lack Snail1 
expression. Introducing mutated BRAF into primary mela-
nocytes resulted in increased Snail1 expression and reduced 
    Figure 8.         Model of the regulation of Snail and how Snail affects 
proliferation, as well as migration and invasion, via suppression of 
CYLD.   In melanoma cells, constitutively high ERK-activity (potentially 
caused by B-Raf mutations) leads to high Snail1 expression, which in turn 
causes strong suppression of CYLD. The repression of CYLD allows nuclear 
translocation of Bcl-3 and recruitment to the NF-    B binding sites of the 
Cyclin D1 and N-cadherin promoter. Activation of Cyclin D1 and N-cad-
herin leads to an increased proliferation rate of melanoma cells and con-
tributes to progression and metastasis of tumors.     230 SNAIL1 REGULATES CYLD IN MELANOMA   | Massoumi et al. 
any detectable nuclear staining, and CYLD staining intensity was specifi  ed 
applying a semiquantitative three-step scoring system (score 0, negative; 
score 1+, weak; and score 2+, strong cytoplasmic staining). Examples for 
positive and negative CYLD and Snail1 stainings are given in   Fig. 7 E  . Intra-
cellular BCL-3 localization was visualized by immunofl  uorescence analysis 
using an anti  –  BCL-3-antibody (1:200; Santa Cruz Biotechnology, Inc.). 
  Proliferation, colony formation in soft agar, migration, and inva-
sion assays.     Cell proliferation was determined by means of BrdU incorpo-
ration into cellular DNA using an ELISA-based colorimetric assay (Roche). 
Colony formation in soft agar, monolayer scratch assays, spheroid migration 
assays, and migration and invasion assays in Boyden chambers were per-
formed as previously described (  40, 41  ). 
  ChIP.     ChIP was performed according to the manufacturer  ’  s (IMGENEX 
Corporation) instructions using polyclonal antibodies against Snail1 (clone 
E-18; Santa Cruz Biotechnology, Inc.), p50, p52, Snail2, Twist (Abcam), 
or BCL-3 (Santa Cruz Biotechnology, Inc.), and negative control rabbit 
immunoglobulin (DAKO) as control. The extracted DNA was used for 
semiquantitative PCR to amplify the   Cyclin D1  ,   N-cadherin  ,   IL-10  , or 
  CYLD   promoter region (Table S3, available at http://www.jem.org/cgi/
content/full/jem.20082044/DC1). 
  Transfection of carcinoma cell lines.     Expression plasmids of CYLD, N-
cadherin, or BCL-3 were used for transient transfection applying the Lipo-
fectamine plus method (Invitrogen) (  35, 36  ). BRAF plasmids (C. Wellbrook, 
University of Manchester, Manchester, England, UK) and Snail expression 
constructs (A. Garcia de Herreros, Institute Municipal, Barcelona, Spain) 
were also used. Stable expression of CYLD, C/S-CYLD, CYLD siRNA, 
and GFP was achieved by retro- or lentiviral gene transfer (  42  ). In brief, 
CYLD and GFP were cloned into a retroviral vector (pclMFG). CMV pro-
moter-driven lentiviral constructs were obtained by cloning wt-HA-CYLD, 
C/S-HA-CYLD, and GFP into a HIV-1  –  derived lentiviral vector (  42  ). 
  Transfection with CYLD siRNA (  43  ) or BCL-3 siRNA (  17  ) was per-
formed as previously described using HiPerfect according to the manufactur-
er  ’  s recommendations (Invitrogen), and the transfection effi   ciency was     40%. 
siRNA oligos were purchased from TAG Copenhagen A/S with the following 
RNA sequences: Scramble (5'-AGACCCACUCGGAUGUGAAGAGAUA-
3') and Snail1 697 (5'-GUGAAGAGAUACCAGUGUCAGGCCU-3'). 
  Reporter gene assays.     The reporter gene assays with CYLD, Cyclin D1, 
or N-cadherin promoter-luciferase plasmids were performed as previously 
described (  17, 27, 36  ). 
  Statistical analysis.     Values are presented as means   ±   SEM. Statistical diff  er-
ences were determined using Student  ’  s   t   test. Contingency table analysis and 
two-sided Fisher  ’  s exact tests were used to study the statistical association 
between categorical clinicopathologic and immunohistochemical variables. 
Retrospective overall survival and progression-free survival curves compar-
ing patients with and without any of the variables were calculated using the 
Kaplan-Meier method, with signifi  cance evaluated using log-rank statistics. 
For the progression-free survival analysis, patients were censored at the time 
of their last tumor-free clinical follow-up appointment. For the overall sur-
vival analysis, patients were censored at the time of their last clinical follow-
up appointment. Median overall survival time for censored patients was 63.5 mo 
(range, 3  –  135 mo). P   <   0.05 was considered signifi  cant. Statistical analyses 
were performed using SPSS version 10.0 (SPSS, Inc.). 
  Online supplemental material.     Fig. S1 shows the CYLD promoter se-
quence. Fig. S2 shows mRNA and protein expression of Snail and Slug in 
malignant melanoma cell lines. Fig. S3 includes data on the eff  ect of CYLD 
analyzed in Mel Im as Snail clone 2. Fig. S4 shows the eff  ect of CYLD 
on subcellular localization of Bcl-3. In Fig. S5, the eff  ects of CYLD on 
proliferation and migration of Mel Juso melanoma cells in vitro are pre-
sented, and in Fig. S6 the eff  ects of CYLD on in vivo proliferation and 
    MATERIALS AND METHODS   
  Cells, cell culture, and mouse models.     The melanoma cell lines Mel Ei, 
Mel Wei, Mel Ho, and Mel Juso were derived from a primary cutaneous 
melanoma. Mel Im and Mel Ju were derived from metastases of malignant 
melanomas (J. Johnson, Ludwig Maximilian University of Munich, Munich, 
Germany) (  35  ). Furthermore, melanoma cells were freshly isolated from pri-
mary human melanomas and used at low passage to confi  rm key fi  ndings 
obtained with melanoma cell lines. All primary melanoma cells and cell lines 
used carried the V600E mutation in BRAF. Isolation and culture of primary 
NHEMs (  35  ) and 5-azacytosine (10 mM) treatment for analysis of promoter 
methylation were performed as previously described (  36  ). 
  Melanoma cells and NHEMs were treated with the chemical MAPK 
inhibitors SP600125 (specifi  c for JNK1, JNK2, and JNK3), PD98059, and 
UO126 (specifi  c for MEK1 and MEK2; all from Calbiochem) at a concen-
tration of 20   μ  M for 19 h. The vehicle DMSO alone served as control. 
  Tumor cell inoculation and measurement of tumor growth in NMRI 
(  nu/nu  ) mice was performed as previously described (  37  ). For analysis of in 
vivo metastasis melanoma, cells were injected i.v. (10  6   cells/mouse). 4 wk 
after inoculation, lungs were processed for (immuno-)histology, and intra-
pulmonary metastases were counted for one representative section per mouse 
using MART 1 (1:100; Novus Biologicals) and MIA (  38  ) staining to deter-
mine metastasis. In addition, MIA serum levels were determined using a 
MIA-ELISA (Roche). Experiments were approved by the Department of 
Veterinary Aff  airs of the local Government of Bavaria, District of Oberp-
falz Area. 
  Isolation of tumorous and nontumorous human tissues.     Tissue 
samples from primary human melanoma, and melanoma metastasis ob-
tained from patients undergoing surgical treatment, were immediately snap 
frozen and stored at     80  °  C. Melanoma cells were selectively retrieved 
from tumor samples with PALM microlaser technology (PALM) under 
microscopic control. 
  The tissue microarray was constructed as previously described (  39  ) and 
contained primary unifocal malignant melanomas. Clinical follow up data 
from the Central Tumor Registry were available for all patients. The median 
follow up for all patients was 54 mo (range 1  –  135 mo). The University of 
Regensburg Institutional Review Board granted approval for the project. 
  Expression analysis.     Isolation of total cellular RNA from cultured cells 
and tissues and reverse transcription were performed as previously described 
(  36  ). To ensure expression of the full-length CYLD mRNA, RT-PCR 
analysis was performed using two specifi  c primer combinations (Table S1, 
available at http://www.jem.org/cgi/content/full/jem.20082044/DC1) 
and the PCR products were resolved on 1.5% agarose gels. Sequences were 
examined by automated sequencing. Quantitative real time-PCR was per-
formed with specifi  c primers for CYLD, Cyclin D1, N-cadherin, and Snail1 
(Table S2) applying LightCycler technology (Roche), as previously de-
scribed (  36  ). 
  Protein analysis.     Protein extraction, analysis, and Western blotting were 
performed as previously described (  36  ), applying the following primary anti-
bodies: polyclonal anti-CYLD (1:1,000 [  17  ]), anti  –  Cyclin D1 (1:500; Santa 
Cruz Biotechnology, Inc.), anti  –  BCL-3 (1:250; Santa Cruz Biotechnology, 
Inc.), anti  –  N-cadherin (1:2,000; BD), anti-ERK1/2 (1:1,000), anti  –  Lam-
inin A/C (1:1,000) or anti-phospho-ERK1/2 (1:1,000; Cell Signaling 
Technology), anti-Snail1 (1:500; Abcam), anti-Snail2 (1:500; Abcam), anti-
Twist (1:500; Abcam), anti-tubulin (1:1,000; Millipore), or anti  –      -actin 
(1:5,000; Sigma-Aldrich). 
  Immunohistochemical and immunofl   uorescence analysis of paraffi   n-
embedded tissues applying anti-CYLD antibody (1:1,500), anti-Snail1 anti-
body (1:50), or anti-tyrosinase antibody was performed as previously 
described (  17, 36  ). For negative control, the primary antibody was omitted 
and IgG isotype control antibodies did not reveal any detectable staining. 
Immunohistochemical stainings were counterstained with hematoxylin. For 
analysis of the tissue, microarray positivity for Snail1 was therefore defi  ned as JEM VOL. 206, January 19, 2009 
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